Anzeige
Meldung des Tages: Ein Gold-Asset in der Champions League der Geologie – Erstklassige Lage im „Land der Giganten“

BioLineRX Aktie (ADR) News

Aktie
WKN:  A41038 ISIN:  US09071M3043 US-Symbol:  BLRX Branche:  Biotechnologie Land:  Israel
2,16 €
-0,005 €
-0,23%
08:01:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
4,96 Mio. €
Streubesitz
94,93%
KGV
-3,67
Index-Zuordnung
-

BioLineRX Aktie (ADR) News

24.11.25 - PR Newswire
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
18.11.25 - PR Newswire
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire
17.11.25 - PR Newswire
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types PR Newswire
29.09.25 - PR Newswire
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-​in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other ...
14.08.25 - PR Newswire
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
07.08.25 - PR Newswire
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 PR Newswire
30.05.25 - PR Newswire
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-​Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting ...
27.05.25 - PR Newswire
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
20.05.25 - PR Newswire
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
BioLineRx to Report First Quarter 2025 Results on May 27, 2025 PR Newswire
31.03.25 - PR Newswire
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
BioLineRx Reports 2024 Financial Results and Provides Corporate Update PR Newswire
24.03.25 - PR Newswire
BioLineRx to Report 2024 Annual Results on March 31, 2025
BioLineRx to Report 2024 Annual Results on March 31, 2025 PR Newswire

Newssuche

Videos

newspaper
18.02.26 0,00%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Antimon-Preis verdreifacht
Antimony Resources Corp
0,4461 €
-5,79%
Antimony Resources Corp Chart
Startet jetzt der nächste Rohstoff-Run?
Mehr zur Aktie »